SONOSCAPE(SZ:300633) Sou Hu Cai Jing·2026-01-16 12:22Core Viewpoint - The stock of Kaili Medical (300633) has experienced a decline, with significant changes in its financial performance and capital flow, indicating potential investment opportunities and risks in the medical equipment sector [1][2]. Financial Performance - For the first three quarters of 2025, Kaili Medical reported a main revenue of 1.459 billion yuan, an increase of 4.37% year-on-year [2]. - The net profit attributable to shareholders was 33.51 million yuan, a decrease of 69.25% year-on-year [2]. - The net profit after deducting non-recurring items was 23.99 million yuan, down 72.14% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 495 million yuan, up 28.42% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -13.52 million yuan, an increase of 78.05% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -15.89 million yuan, an increase of 76.92% year-on-year [2]. - The company's debt ratio stands at 24.22%, with investment income of 2.08 million yuan and financial expenses of -38.30 million yuan [2]. - The gross profit margin is reported at 60.36% [2]. Stock Performance and Capital Flow - As of January 16, 2026, Kaili Medical's stock closed at 28.81 yuan, down 3.13%, with a turnover rate of 1.22% and a trading volume of 52,900 lots, amounting to a total transaction value of 154 million yuan [1]. - On January 16, the net outflow of main funds was 27.89 million yuan, accounting for 18.13% of the total transaction value [1]. - The net inflow of retail funds was 13.13 million yuan, representing 8.54% of the total transaction value [1]. - Over the past 90 days, 10 institutions have provided ratings for the stock, with 8 buy ratings and 2 hold ratings [2]. - The average target price set by institutions over the past 90 days is 39.71 yuan [2].